![]() In their report, the investigators wrote that there were 15 recurrences, overall, in the 48-patient cohort. In contrast to some previous studies of Natera's approach, which compared post-adjuvant Signatera surveillance every three months to imaging at one and three years (a standard of practice in some ex-US areas), patients in the City of Hope cohort were imaged at the NCCN-recommended initial intervals of either three months, six months, or one year, depending on stage. ![]() The researchers compared Signatera ctDNA results, most obtained after adjuvant therapy, to the standard of care recommended by the National Comprehensive Cancer Network, which includes CT scans and carcinoembryonic antigen (CEA) testing. Of these, 31 patients had stage II-III cancer and another 17 had stage IV tumors. Investigators analyzed data from 48 individuals who had had their colorectal cancer resected between September 2019 and November 2021. The study is a small one, but it provides evidence both that ctDNA can preclude radiologic detection of recurrence, and that, in the context of US-based screening recommendations, it often may not. Natera's stock was down around 31 percent at $37.66 in Wednesday afternoon trading on the Nasdaq, likely reflecting investors' reaction to the study and a negative report about Natera's business published by short sellers Hindenburg Research. In contrast, imaging plus proteomic testing identified 11 cancer recurrences in patients without being preempted by circulating tumor DNA (ctDNA) assay-positivity at an earlier time point. In the study, published Tuesday in JAMA Network Open, Signatera caught the first sign of recurrence in eight of the 15 patients who recurred in the study, although some cases were also simultaneously, or contemporaneously, identified by imaging. NEW YORK – Researchers at City of Hope have published a new study calling into question the reliability and utility of Natera's Signatera assays for recurrence monitoring in colorectal cancer patients, highlighting the results as evidence that genomic minimal residual disease (MRD) testing may be at best unhelpful and at worst unreliable in detecting recurrences earlier than standard-of-care imaging and blood protein tests. I'm glad I wasn't contacted, as I wouldn't want to work with people like this anyways.This story has been updated from a previous version to note that the drop in Natera's stock price Wednesday was likely attributable to a negative report about the company from short sellers Hindenburg Research, not solely the City of Hope research paper as originally reported. No one had the respect/decency to follow up with me after my SEVERAL interviews and 5 references. After our interview I sent thank you emails and even followed up regarding status updates weeks after. In an effort to gain their attention, I tried speaking louder during one of the questions and they responded in a way that suggested I would not have good customer service skills. They both did not crack one smile and spoke in VERY monotonous voices. They would take turns asking me questions while being on their phones. Despite my eager, up-beat tone, my interviewers were both on their phones the entire time (let me also mention one of them was also late and coming in and out of the interview after being late). ![]() ![]() My last interview was with 2 pharmacists and it was quite the opposite of pleasant. I actually was asked to complete 5 references after my 2nd interview (if that isn't a sign I would get the job I don't know what is). My first 2 interviews went well and were overwhelmingly positive. I applied online. I interviewed at City of Hope (Duarte, CA) in Dec 2020 Interview ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |